Rate Control in Ischemic Heart Disease with Concentric LV Remodeling and Pulmonary Hypertension

Primary Rate‑Control Strategy

Beta‑blockers are the first‑line agents for rate control in patients with ischemic heart disease, even when concentric LV remodeling and moderate pulmonary hypertension are present. The ACC/AHA guideline assigns this recommendation a Class I, Level B rating. [@1]
The ACC/AHA guideline designates beta‑blockers as Class I, Level B first‑line therapy, superior to digoxin or calcium‑channel blockers for rate control in ischemic heart disease. [@1][@3]
Bisoprolol, carvedilol, and sustained‑release metoprolol succinate are the preferred beta‑blockers for this population. [@4]

If optimal beta‑blocker therapy does not achieve target heart rate, add digoxin rather than a non‑dihydropyridine calcium‑channel blocker. ACC/AHA recommendation. [@1][@7]
Digoxin 0.125–0.25 mg daily provides synergistic AV‑node blockade when combined with a beta‑blocker. [@1][@7]
The combination of a beta‑blocker plus digoxin effectively controls both resting and exercise heart rates. ACC/AHA guidance. [@1][@2][@7]

Non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) should be avoided in any patient with LV systolic dysfunction or decompensated heart failure. ACC/AHA recommendation. [@1][@2][@5]
ESC guidelines advise avoiding non‑dihydropyridine calcium‑channel blockers in heart failure with reduced ejection fraction. [@1]
ACC/AHA guidelines state that these agents should be used only with extreme caution in HFrEF. [@1]
In patients with concentric remodeling and pulmonary hypertension, non‑dihydropyridine calcium‑channel blockers may worsen hemodynamic compromise. [@2][@5]
They are classified as Class III (harm) in decompensated heart failure. [@5][@8]

When beta‑blocker + digoxin therapy is insufficient, intravenous amiodarone can be employed for acute rate control (150 mg over 10 min, then 1 mg/min for 6 h, then 0.5 mg/min). ACC/AHA guidance. [@1][@2][@5]
AV‑node ablation with permanent pacemaker implantation is reasonable when pharmacologic therapy is ineffective or not tolerated. ESC/ACC/AHA consensus. [@2][@5][@8]

Rate‑control adequacy must be evaluated during activity, not solely at rest. ACC/AHA recommendation. [@5][@8]
Target resting heart rate: 60–80 bpm for strict control; < 110 bpm is acceptable (lenient control) if the patient is asymptomatic. [@5]
Target exercise heart rate: 90–115 bpm during moderate activity. [@5]

Beta‑blockers reduce myocardial oxygen demand and enhance ischemic preconditioning. Class I evidence. [@6]
In acute ischemia with rapid ventricular response, intravenous metoprolol (2.5–5 mg every 2–5 min) or intravenous diltiazem (0.25 mg/kg over 2 min) are appropriate options. ACC/AHA guidance. [@9][@5]
Hemodynamic instability mandates immediate electrical cardioversion rather than pharmacologic rate control. Class I recommendation. [@1][@5]

Target blood pressure < 130/80 mmHg; avoid excessive diastolic lowering below 60 mmHg in ischemic heart disease. Class I, Level A evidence. [@3]
ACE inhibitors or ARBs should be added for blood‑pressure control and cardioprotection in ischemic heart disease. Class I recommendation. [@6][@3]
Thiazide diuretics may be added for additional blood‑pressure reduction and volume management. Class I recommendation. [@6][@3]